Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation

Carcinogenesis

Volumn 28, Issue 5, 2007, Pages 957-961

  Myrdal, P B ^b   Karlage, K ^b   Kuehl, P J ^b   Angersbach, B S ^b   Merrill, B A ^a   Wightman, P D ^a  

^a 3M COMPANY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BENZO[A]PYRENE; LIPOXYGENASE INHIBITOR; S 29606; S 30621; UNCLASSIFIED DRUG; ZILUETON; ARACHIDONATE 5 LIPOXYGENASE; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; HYDROXAMIC ACID; HYDROXYUREA; ZILEUTON;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG STRUCTURE; EX VIVO STUDY; FEMALE; LOW DRUG DOSE; LUNG ADENOMA; MOUSE; NEBULIZER; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; ADENOMA; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; INCIDENCE; INHALATIONAL DRUG ADMINISTRATION; LUNG TUMOR; MOUSE STRAIN; ORAL DRUG ADMINISTRATION;

ADENOMA; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BENZO(A)PYRENE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDROXAMIC ACIDS; HYDROXYUREA; INCIDENCE; LIPOXYGENASE INHIBITORS; LUNG NEOPLASMS; MICE; MICE, INBRED STRAINS; PHENYLUREA COMPOUNDS;

EID: 34447094488     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl216     Document Type: Article

References (27)

1. American Cancer Society. (2006) Cancer Facts and Figures 2006. American Cancer Society, Atlanta, GA.
2. Rioux, N. et al. (1998) Inhibitors of lipoxygenase: A new class of cancer chemopreventive agents. Carcinogenesis, 19, 1393-1400.
3. Steele, V.E. et al. (1999) Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev., 8 467-483.
4. Hussey, H.J. et al. (1996) Inhibition of tumor growth by lipoxygenase inhibitors. Br. J. Cancer, 74, 683-687.
5. Avis, I.M. et al. (1996) Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J. Clin. Invest., 97, 806-813.
6. La, E. et al. (2003) Fatty acid release and oxidation are factors in lipoxygenase inhibitor-induced apoptosis. Toxicol. Lett., 138, 193-203.
7. Gunning, W.T. et al. (2002) Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res., 62, 4199-4201.
8. Gunning, W.T. et al. (2000) Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice. Exp. Lung Res., 26, 757-772.
9. Kisley, L.R. et al. (2002) Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis, 23, 1653-1660.
10. Wattenberg, L.W. et al. (1997) Studies of chemopreventive effects of budesonide on benzo(a)pyrene-induced neoplasia of the lung of female A/J mice. Carcinogenesis, 18, 2015-2017.
11. Witschi, H. et al. (2000) Chemoprevention of tobacco-smoke lung carcinogenesis in mice after cessation of smoke exposure. Carcinogenesis, 21, 977-982.
12. Wattenberg, L.W. et al. (2000) Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone diproprionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis, 21, 179-182.
13. Wattenberg, L.W. et al. (1997) Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res., 57, 5489-5492.
14. Crooks, S.L. et al. Method of inhibiting leukotriene biosynthesis. USPTO 5,612,377. 18 March 1997.
15. Wightman, P.D. et al. (1990) Regulation of phosphatidylinositol breakdown and leukotriene synthesis by endogenous prostaglandins in resident mouse peritoneal macrophages. J. Biol. Chem., 265, 9176-9180.
16. Sweeney, F.J. et al. (1987) Development of a system for evaluating 5-lipoxygenase inhibitors using human whole blood. Prostaglandins Leukot. Med., 28, 73-93.
17. Guyton, A.C. (1947) Measurement of the respiratory volumes of laboratory animals. Am. J. Physiol., 150, 70-77.
18. Stein, S.W. et al. (2003) Evaluation of a new aerodynamic particle sizer for size distribution measurements of solution metered dose inhalers. J. Aerosol Med., 16, 107-119.
19. Wexler, H. (1966) Accurate identification of experimental pulmonary metastases. J. Natl Cancer Inst., 36, 641-645.
20. ClogP for Windows, Version 4.0, 1995-1999. Biobyte Corp.
21. Henderson, R.F. et al. (1988) The effect of molecular weight/ lipophilicity on clearance of organic compounds from lungs. Toxicol. Appl. Pharmacol., 95, 515-521.
22. 2 synthetase, on eicosanoid production. Eur. J. Pharmacol., 422, 209-216.
23. Dubé, L.M. et al. (1998) Zileuton: The first leukotriene inhibitor for use in the management of chronic asthma, in: Drazen, J.M., Dahlén, S. and Lee, T.H. (eds.) Five-Lipoxygenase Products in Asthma. Marcel Dekkar, Inc., New York, NY, pp. 394.
24. Powell, W.S. et al. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Progress in Lipid Research, 44, 154-183.
25. Critical Therapeutics, Inc.Zyflo® Zileuton Tablets Full Prescribing Information, http://www.zyflo.com/patient/prescribing.html (23 May 2006 date last accessed).
26. Roy, CJ. et al. (2003) Impact of inhalation exposure modality and particle size on the respiratory deposition of ricin in BALB/c mice. Inhal. Toxicol., 15, 619-638.
27. Wheelan, P. et al. (1997) Quantitation of 5-lipoxygenase products by electrospray mass spectrometry: Effect of ethanol on zymosan-stimulated production of 5-lipoxygenase products by human neutrophils. Anal. Biochem., 244, 110-115.